Tempus AI, Inc. (NASDAQ:TEM) Receives $78.62 Consensus Target Price from Analysts

Tempus AI, Inc. (NASDAQ:TEM) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $78.6154.

Several research firms recently commented on TEM. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Morgan Stanley lowered their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. Canaccord Genuity Group reduced their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Finally, HC Wainwright increased their target price on shares of Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, March 9th.

Tempus AI Stock Performance

Shares of TEM opened at $42.62 on Thursday. The company has a market capitalization of $7.62 billion, a price-to-earnings ratio of -30.23 and a beta of 5.29. Tempus AI has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The stock has a 50 day moving average price of $55.11 and a 200 day moving average price of $69.65.

Insider Activity

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James William Rogers sold 10,084 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the transaction, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This trade represents a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 568,841 shares of company stock worth $32,579,611 over the last quarter. 26.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. Cranbrook Wealth Management LLC purchased a new position in Tempus AI during the 3rd quarter worth $25,000. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter worth $26,000. GAMMA Investing LLC purchased a new stake in shares of Tempus AI in the third quarter valued at about $28,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $27,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI during the third quarter worth about $38,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus “Moderate Buy” rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.